Recombinant Anti-Human CD38 VHH Single Domain Antibody

Customer Review

There are currently no Customer reviews or questions for NABL-079. Click the button above to contact us or submit your feedback about this product.

Sarah Martinez
09.May,23

Great for CD38 Detection

The Anti-CD38 VHH Single Domain Antibody has been excellent for our CD38 detection assays. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

Brian Green
23.Aug,22

Effective and Reliable

We incorporated this antibody into our flow cytometry and immunofluorescence assays, and it has been a great asset. The specificity for CD38 is precise, allowing for accurate cell population analysis. The reliable performance has made it an invaluable tool in our lab.

Megan White
12.Sep,21

Consistent High-Quality Results

This antibody has proven to be consistent and reliable in our assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for CD38 have been particularly beneficial.

Q&As

1. Is the anti-CD38 VHH single domain antibody effective in ELISA applications?

   A: Yes, the anti-CD38 VHH single domain antibody (NABL-079) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of CD38.

2. What is the optimal dilution for using the anti-CD38 VHH single domain antibody in flow cytometry?

   A: The optimal dilution for using the anti-CD38 VHH single domain antibody (NABL-079) in flow cytometry is typically 1:50 to 1:200. It is recommended to perform a dilution series to determine the best working concentration for specific experimental conditions.

3. Can the anti-CD38 VHH single domain antibody be used in immunoprecipitation assays?

   A: Yes, the anti-CD38 VHH single domain antibody (NABL-079) can be used in immunoprecipitation assays. It provides specific binding to CD38, enabling the successful precipitation of the target protein from complex mixtures.

4. Is this anti-CD38 VHH single domain antibody suitable for use in Western blotting?

   A: Yes, the anti-CD38 VHH single domain antibody (NABL-079) is suitable for use in Western blotting. It provides specific binding to CD38, allowing for reliable detection in Western blot assays.

5. What are the storage recommendations for the anti-CD38 VHH single domain antibody?

   A: The recommended storage condition for the anti-CD38 VHH single domain antibody (NABL-079) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Chatterjee, Shilpak, et al. "CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response." Cell metabolism 27.1 (2018): 85-100. https://doi.org/10.1016/j.cmet.2017.10.006
   The research investigates the role of the CD38-NAD+ axis in regulating anti-tumor T cell responses in immunotherapy. The study demonstrates that hybrid Th1/17 cells, which combine the effector properties of Th1 cells with the stemness features of Th17 cells, exhibit superior tumor control capabilities. These hybrid cells show enhanced intracellular NAD+ levels, which activate the histone deacetylase Sirt1, leading to deacetylation and activation of the transcription factor Foxo1. This NAD+-Sirt1-Foxo1 pathway is crucial for maintaining both the effector function and long-term persistence of T cells. Importantly, the expression of CD38, which functions as a NADase, inversely correlates with NAD+ levels and regulates the anti-tumor potential of T cells. The researchers found that genetic ablation or antibody-mediated targeting of CD38 on T cells increased NAD+ levels and improved tumor control.
   Creative Biolabs provided an anti-CD38 VHH Single Domain Antibody (CAT#: NABL-079) that played a significant role in this research. This antibody was used to block CD38 expression on T cells, which helped demonstrate that antibody-mediated targeting of CD38 could enhance T cell-mediated tumor control. By inhibiting CD38 with this antibody, the researchers showed that it's possible to metabolically reprogram T cells to maintain higher NAD+ levels, leading to improved oxidative phosphorylation, enhanced glutaminolysis, and altered mitochondrial dynamics, all of which contributed to superior tumor control even when using non-specialized Th0 anti-tumor T cells.
2. Chatterjee, Shilpak, et al. "CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response." Cell metabolism 27.1 (2018): 85-100. https://doi.org/10.1016/j.cmet.2017.10.006
   This study investigates the role of CD38-mediated NAD+ metabolism in the anti-tumor function of T cells. The researchers explored how CD38 expression influences the metabolic pathways of T cells within the tumor microenvironment, specifically focusing on its impact on mitochondrial biogenesis and function. By analyzing CD38-deficient and wild-type T cells, the study demonstrated that CD38 plays a crucial role in regulating NAD+ levels, which in turn affects the T cells' metabolic fitness and anti-tumor capabilities. The findings suggest that targeting CD38 could enhance the efficacy of T cell-based immunotherapies by improving T cell metabolism and function within tumors.
   Creative Biolabs provided critical reagents for this study, including the Anti CD38 VHH Single Domain Antibody (Cat# NABL-079). This antibody was essential for the experiments involving CD38 detection and functional analysis in T cells. By enabling precise measurement and modulation of CD38 activity, the antibody facilitated a deeper understanding of how CD38 regulates T cell metabolism and its potential as a therapeutic target. The contribution of Creative Biolabs' products significantly advanced the study's investigation into enhancing T cell-mediated anti-tumor responses through metabolic modulation.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# NABL-079, RRID: AB_3111560)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "CD38"

Select a product category from the dropdown menu below to view related products.